Eton Pharmaceuticals (ETON) Investor Day 2025 summary

Strategic Vision and Growth Pillars

• Focused on building a leading ultra-rare disease company with a patient-first philosophy and high-touch assistance programs.

• Three-pillar growth strategy: organic growth, internal pipeline development, and external acquisitions/licensing.

• Portfolio expanded to 13 approved or late-stage ultra-rare products, with five added in the last six months.

• Commercial strategy leverages deep relationships in pediatric, endocrinology, and metabolic genetics communities, and strong partnerships with advocacy groups.

• Launched new metabolic sales force and executed successful commercial launches.

Financial Performance and Outlook

• Achieved 16 consecutive quarters of product sales growth, reaching $39 million in 2024, up from $3 million in 2021.

• Q4 2024 revenue was $11.6 million, a 59% year-over-year increase, driven by Carglumic Acid and Alkindi Sprinkle.

• Gross profit rose 78% year-over-year; SG&A increased due to acquisitions and launch preparations.

• 2025 adjusted gross margin expected to reach ~70%, with a long-term target of 75% by 2028 as higher-margin products grow.

• On track to exit 2025 at ~$80M annual revenue run rate, with a clear path to $100M+ near-term revenue.

Increlex Acquisition and Growth Strategy

• Increlex treats severe primary IGF-1 deficiency (SPIGFD) in children; only 200 US patients, but label harmonization could expand this to 1,000.

• Rapid relaunch: 67 to 81 active patients in three months, aiming for over 100 by year-end and a path to 185 (historical peak).

• Growth levers include increased awareness, price adjustment, expanded financial assistance, and potential US/EU label harmonization.

• FDA meeting for label update expected mid-2025; potential label revision in H1 2026.

• If label harmonization succeeds, US market opportunity could grow from $55 million to $250 million annually.